Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics has released a brief corporate communication noting that some of its January 2026 corporate presentation may include statements that qualify as forward-looking under U.S. securities laws. The company cautions that such statements, including any financial projections or discussions of strategic plans and objectives, are subject to risks and uncertainties that could cause actual results to differ materially, and it directs investors to its 2025 Form 20-F risk factors for further detail, underscoring the regulatory and risk-awareness context around its investor communications.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Average Trading Volume: 15,439,779
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.